Kura Oncology Inc (KURA) - Total Liabilities
Based on the latest financial reports, Kura Oncology Inc (KURA) has total liabilities worth $544.67 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore KURA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Kura Oncology Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how Kura Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Kura Oncology Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Kura Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Kura Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Air New Zealand Ltd
AU:AIZ
|
Australia | AU$7.31 Billion |
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
China | CN¥1.09 Billion |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
Thailand | ฿3.28 Billion |
|
Hemnet Group AB
ST:HEM
|
Sweden | Skr1.14 Billion |
|
Zhejiang Great Southeast Co Ltd
SHE:002263
|
China | CN¥169.32 Million |
|
Sharda Cropchem Limited
NSE:SHARDACROP
|
India | Rs22.27 Billion |
|
HMT Limited
NSE:HMT
|
India | Rs24.87 Billion |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
China | CN¥720.47 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Kura Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KURA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kura Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kura Oncology Inc (2009–2025)
The table below shows the annual total liabilities of Kura Oncology Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $564.23 Million | +62.83% |
| 2024-12-31 | $346.52 Million | +570.74% |
| 2023-12-31 | $51.66 Million | +43.39% |
| 2022-12-31 | $36.03 Million | +31.29% |
| 2021-12-31 | $27.44 Million | -24.42% |
| 2020-12-31 | $36.31 Million | +56.56% |
| 2019-12-31 | $23.19 Million | +8.40% |
| 2018-12-31 | $21.39 Million | +33.83% |
| 2017-12-31 | $15.99 Million | +23.49% |
| 2016-12-31 | $12.95 Million | +151.07% |
| 2015-12-31 | $5.16 Million | +7.17% |
| 2014-12-31 | $4.81 Million | +3516.61% |
| 2013-12-31 | $133.03K | +28.34% |
| 2012-12-31 | $103.65K | +38.66% |
| 2011-12-31 | $74.75K | +6.20% |
| 2010-12-31 | $70.39K | +122.66% |
| 2009-12-31 | $31.61K | -- |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more